ALK and lung carcinoma: The simultaneous discovery of potential toxic effects of certain tyrosine kinase inhibitors in patients with ALK rearrangement who had received previous immunotherapy provides evidence for the need for further refinement of genetic testing before treatment of patients with lung cancer.